J. Grarup

发表

Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial

J. Vestbo, J. Lundgren, H. C. Boesen, 2016, Annals of Intensive Care.

Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.

J. Sterne, O. Kirk, A. d’Arminio Monforte, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro

T. Christoph, J. Grarup, J. Berg, 1999, Inflammation Research.

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

A. Antinori, F. Raffi, G. Chêne, 2014, The Lancet.

Lolland-Falster Health Study: Study protocol for a household-based prospective cohort study

J. Brodersen, E. Simonsen, C. Ellervik, 2018, Scandinavian journal of public health.

A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

A. Mocroft, O. Kirk, A. Phillips, 2014, Infection.

Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults

A. Mocroft, C. Sabin, M. Battegay, 2015, AIDS.

All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2012, International journal of epidemiology.

Lessons learned: Infrastructure development and financial management for large, publicly funded, international trials

M. Vjecha, F. Hudson, Cate Carey, 2016, Clinical trials.

Children and young people with perinatal HIV in Europe: epidemiological situation in 2014 and implications for the future

M. Sandhu, O. Kirk, M. Rosińska, 2016 .

Invasive Candida Infections and the Harm From Antibacterial Drugs in Critically Ill Patients: Data From a Randomized, Controlled Trial to Determine the Role of Ciprofloxacin, Piperacillin-Tazobactam, Meropenem, and Cefuroxime*

J. Lundgren, M. Arendrup, J. Jensen, 2015, Critical care medicine.

Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes.

A. Mocroft, H. Günthard, D. Podzamczer, 2013, The Journal of infectious diseases.

The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.

B. Gazzard, A. Mocroft, O. Kirk, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)

Anne M Johnson, Hansjakob Furrer, Peter Reiss, 2013, PLoS medicine.

CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE

B. Gazzard, O. Kirk, H. Furrer, 2012, PLoS medicine.

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.

A. Mocroft, D. Podzamczer, A. Phillips, 2012, The Lancet. Infectious diseases.

Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe

A. Mocroft, D. Podzamczer, A. Phillips, 2011, Journal of acquired immune deficiency syndromes.

Risk of triple-class virological failure in children with HIV: a retrospective cohort study

A. Phillips, D. Costagliola, D. Gibb, 2011, The Lancet.

Efficacy of etravirine combined with darunavir or other ritonavir‐boosted protease inhibitors in HIV‐1‐infected patients: an observational study using pooled European cohort data

J. Lundgren, V. Calvez, F. Ceccherini‐Silberstein, 2015, HIV medicine.

Clinical Application of Variation in Replication Kinetics During Episodes of Post-transplant Cytomegalovirus Infections

A. Mocroft, J. Lundgren, H. Sengeløv, 2015, EBioMedicine.

Lolland-Falster Health Study

J. Brodersen, E. Simonsen, C. Ellervik, 2018 .

Challenges, successes and patterns of enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

F. Hudson, E. Denning, C. Rappoport, 2015, HIV medicine.

The Incidence of AIDS-De fi ning Illnesses at a Current CD 4 Count ≥ 200 Cells / μ L in the Post – Combination Antiretroviral Therapy Era

B. Gazzard, A. Mocroft, O. Kirk, 2013 .

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial

Z. Fox, J. Lundgren, J. Jensen, 2012, BMJ Open.

Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health

Abdel Babiker, Janet Darbyshire, James D Neaton, 2010, Clinical trials.

A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key Populations

C. Morrison, P. Vanhems, A. Kamali, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Investigating the Efficacy of Clinical Trial Monitoring Strategies: Design and Implementation of the Cluster Randomized START Monitoring Substudy

Jonathan M Kagan, Jonathan M. Kagan, K. H. Hullsiek, 2015, Therapeutic innovation & regulatory science.

Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial*

P. L. Petersen, Z. Fox, J. Lundgren, 2011, Critical care medicine.

All-cause mortality in treated HIV-infected adults with CD4 5500/mm compared with the general population: evidence from a large European observational cohort collaborationy

A. Mocroft, O. Kirk, M. Egger, 2022 .

Biomarker-assisted identification of sepsis-related acute liver impairment: a frequent and deadly condition in critically ill patients

J. Lundgren, J. Jensen, M. Bestle, 2019, Clinical chemistry and laboratory medicine.

Acceptance rate of clinical study endpoints and adequacy of source documentation: experience from clinical study endpoint review in NEAT001/ANRS143

F. Wit, F. Raffi, A. Pozniak, 2014, Journal of the International AIDS Society.

Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir–Ritonavir Plus Either Raltegravir or Tenofovir–Emtricitabine: A Substudy of the NEAT001/ANRS143 Trial

H. Amièva, A. d’Arminio Monforte, A. Winston, 2017, Journal of acquired immune deficiency syndromes.

Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic

Henrik Nielsen, L. Mathiesen, C. Leen, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Notification of suspected and unexpected serious adverse reactions according to the Clinical Trials Directive—A descriptive analysis of the legislation and the requirements in a European context

J. Grarup, D. Gey, Karoline B. Jensen, 2010 .

All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2012, International journal of epidemiology.

Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.

J. Sterne, O. Kirk, A. d’Arminio Monforte, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.